Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation

Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the rol...

Descripción completa

Detalles Bibliográficos
Autores: Segura, Àlex G., Martínez Piñeiro, Alberto|||0000-0003-2035-5979, Gassó, Patricia|||0000-0001-6930-3454, Rodríguez, Natalia|||0000-0002-9618-9383, Bioque, Miquel|||0000-0001-6887-7149, Cuesta, Manuel J.|||0000-0003-0250-5718, González-Peñas, Javier|||0000-0002-3850-3012, Garcia Rizo, Clemente|||0000-0002-4855-1608, Lobo, Antonio|||0000-0002-9098-655X, González-Pinto, Ana|||0000-0002-2568-5179, García-Alcón, Alicia, Roldan-Bejarano, Alexandra|||0000-0001-9905-3943, Vieta, Eduard|||0000-0002-0548-0053, Castro-Fornieles, Josefina|||0000-0003-0632-2687, Mané, Anna|||0000-0003-2127-349X, Saiz, Jerónimo, Bernardo, Miquel|||0000-0001-8748-6717, Mas, Sergi|||0000-0003-3336-6298
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:290565
Acceso en línea:https://ddd.uab.cat/record/290565
https://dx.doi.org/urn:doi:10.1016/j.schres.2022.05.021
Access Level:acceso abierto
Palabra clave:Metabolic syndrome
Polygenic risk score
Psychotic disorders
Descripción
Sumario:Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. No major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR ≤ 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.

Similares en LA Referencia